Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
Fusion Pharmaceuticals, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, has announced that the first patient has been dosed in the Phase 1 study for the treatment of solid Tumors. FPI-2059 is a small molecule targeted alpha therapy (TAT) designed to deliver actinium-225 to tumors expressing neurotensin receptor 1 (NTSR1), a protein that is overexpressed in gastrointestinal, prostate, pancreatic ductal adenocarcinoma (PDAC) and multiple other cancers.
“Tremendous opportunity exists in the radiopharmaceutical field to look beyond the few established targets, particularly when using a potent payload like actinium-225. The initiation of the Phase 1 study of FPI-2059 marks an important milestone in this regard, bringing us a step closer to providing a differentiated therapy for patients,” said Chief Executive Officer, John Valliant, Ph.D. “FPI-2059 is our fourth clinical program and the second small molecule-based TAT in our pipeline of radiopharmaceuticals, showcasing the potential for our platform technology to create TATs that treat a broad array of solid tumor types with high unmet need.”
Fusion acquired [177Lu]-IPN-1087 (IPN-1087), a lutetium-based beta-emitting radiopharmaceutical, from Ipsen in April 2021, and converted the compound to the alpha-emitting FPI-2059. In clinical studies, IPN-1087, also referred to as 3BP-227, showed promising early safety data, evidence of anti-tumor activity and uptake in multiple tumor types based on imaging of the distribution of the drug in patients. Fusion showed that in preclinical models, replacing the beta emitter with an alpha emitter resulted in responses at 1,500 times lower administered doses.
The Phase 1, multi-center, open-label clinical trial is designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics of FPI-2059 as well as preliminary anti-tumor activity in participants with neurotensin receptor 1 (NTSR1) expressing advanced metastatic solid tumors. The study will employ a 3+3 dose escalation design to identify the recommended Phase 2 dose (RP2D) of FPI-2059 administered intravenously every 56 days for up to four cycles.
People In This Post
Companies In This Post
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more